FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890745275> ?p ?o ?g. }

• W2890745275 abstract "Both multiple myeloma (MM) and systemic lupus erythematosus (SLE) are associated with abnormal production of plasma cells, although their pathological mechanism of each disease is different. The main characteristic of both diseases is uncontrolled differentiation of B cells into plasmablast/plasma cells. Despite continuous research on prognostic factors and the introduction of new agents for MM and SLE, treatments still do not exist for controlling plasmablast/plasma cells. Thus, it is necessary to identify novel therapeutic targets of plasmablast/plasma cells. Because of its plasmablast-like characteristics, the mus musculus myeloma SP 2/0 cell line was used in this study to test the effect of a novel therapeutic agent (BC094916 overexpression) on plasmablast/plasma cells.We first determined gene expression profiles of plasma cells using Affymetrix microarrays and RNA-sequencing. The effect of BC094916 on SP 2/0 cell proliferation, cell cycle, and apoptosis was determined by CCK8 and fluorescence-activated cell sorting. The SP 2/0 xenograft mouse model was used to assess the impact of BC094916 on tumor progression. The luciferase reporter system was used to evaluate the effect of BC094916 on Creb1 and Bcl2 transcription.We found that BC094916 mRNA was decreased in plasma cells. The mouse myeloma cell line SP 2/0 expressed low levels of BC094916 mRNA, whereas BC094916 overexpression suppressed SP 2/0 cell proliferation by inducing apoptosis. BC094916 overexpression suppressed tumor progression in the SP 2/0 xenograft mouse model. We also found that BC094916 mediate apoptosis by suppressing transcription of the Creb1 and Bcl2 genes, which promote the transcription of eukaryotic translation initiation and elongation factor genes.BC094916 overexpression suppressed Creb1 and Bcl2 transcription to induce cell apoptosis, which suppressed SP 2/0 proliferation and xenograft tumor progression. Thus, BC094916 overexpression may be a potential therapeutic agent for treatment of MM and autoimmune diseases such as SLE." @default.
• W2890745275 created "2018-09-27" @default.
• W2890745275 creator A5005798294 @default.
• W2890745275 creator A5010067937 @default.
• W2890745275 creator A5022484190 @default.
• W2890745275 creator A5042614311 @default.
• W2890745275 creator A5057644948 @default.
• W2890745275 creator A5068380969 @default.
• W2890745275 creator A5071372959 @default.
• W2890745275 creator A5073304731 @default.
• W2890745275 creator A5086664647 @default.
• W2890745275 date "2018-09-14" @default.
• W2890745275 modified "2023-09-25" @default.
• W2890745275 title "BC094916 suppressed SP 2/0 xenograft tumor by down-regulating Creb1 and Bcl2 transcription" @default.
• W2890745275 cites W1495168591 @default.
• W2890745275 cites W1628123357 @default.
• W2890745275 cites W1874291746 @default.
• W2890745275 cites W1952528283 @default.
• W2890745275 cites W1970329605 @default.
• W2890745275 cites W1978302597 @default.
• W2890745275 cites W1988622164 @default.
• W2890745275 cites W1999549312 @default.
• W2890745275 cites W2000119111 @default.
• W2890745275 cites W2018401117 @default.
• W2890745275 cites W2018427441 @default.
• W2890745275 cites W2020721942 @default.
• W2890745275 cites W2040385463 @default.
• W2890745275 cites W2042504787 @default.
• W2890745275 cites W2049439285 @default.
• W2890745275 cites W2056220051 @default.
• W2890745275 cites W2076747220 @default.
• W2890745275 cites W2091675224 @default.
• W2890745275 cites W2094007886 @default.
• W2890745275 cites W2104912263 @default.
• W2890745275 cites W2114898614 @default.
• W2890745275 cites W2118876206 @default.
• W2890745275 cites W2129634935 @default.
• W2890745275 cites W2134979684 @default.
• W2890745275 cites W2156475012 @default.
• W2890745275 cites W2168311146 @default.
• W2890745275 cites W2182463120 @default.
• W2890745275 cites W2304929184 @default.
• W2890745275 cites W2308792635 @default.
• W2890745275 cites W2399851899 @default.
• W2890745275 cites W2472990546 @default.
• W2890745275 cites W2552440568 @default.
• W2890745275 cites W2566095143 @default.
• W2890745275 cites W2738499080 @default.
• W2890745275 cites W2770457793 @default.
• W2890745275 cites W2774888058 @default.
• W2890745275 cites W2785620358 @default.
• W2890745275 cites W2789715803 @default.
• W2890745275 cites W2795765610 @default.
• W2890745275 cites W2799828163 @default.
• W2890745275 cites W2800778103 @default.
• W2890745275 cites W621172456 @default.
• W2890745275 doi "https://doi.org/10.1186/s12935-018-0635-7" @default.
• W2890745275 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6137751" @default.
• W2890745275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30220882" @default.
• W2890745275 hasPublicationYear "2018" @default.
• W2890745275 type Work @default.
• W2890745275 sameAs 2890745275 @default.
• W2890745275 citedByCount "8" @default.
• W2890745275 countsByYear W28907452752019 @default.
• W2890745275 countsByYear W28907452752020 @default.
• W2890745275 countsByYear W28907452752021 @default.
• W2890745275 crossrefType "journal-article" @default.
• W2890745275 hasAuthorship W2890745275A5005798294 @default.
• W2890745275 hasAuthorship W2890745275A5010067937 @default.
• W2890745275 hasAuthorship W2890745275A5022484190 @default.
• W2890745275 hasAuthorship W2890745275A5042614311 @default.
• W2890745275 hasAuthorship W2890745275A5057644948 @default.
• W2890745275 hasAuthorship W2890745275A5068380969 @default.
• W2890745275 hasAuthorship W2890745275A5071372959 @default.
• W2890745275 hasAuthorship W2890745275A5073304731 @default.
• W2890745275 hasAuthorship W2890745275A5086664647 @default.
• W2890745275 hasBestOaLocation W28907452751 @default.
• W2890745275 hasConcept C153911025 @default.
• W2890745275 hasConcept C190283241 @default.
• W2890745275 hasConcept C203014093 @default.
• W2890745275 hasConcept C2776364478 @default.
• W2890745275 hasConcept C2776396001 @default.
• W2890745275 hasConcept C2778630268 @default.
• W2890745275 hasConcept C502942594 @default.
• W2890745275 hasConcept C54355233 @default.
• W2890745275 hasConcept C553184892 @default.
• W2890745275 hasConcept C62112901 @default.
• W2890745275 hasConcept C81885089 @default.
• W2890745275 hasConcept C86803240 @default.
• W2890745275 hasConceptScore W2890745275C153911025 @default.
• W2890745275 hasConceptScore W2890745275C190283241 @default.
• W2890745275 hasConceptScore W2890745275C203014093 @default.
• W2890745275 hasConceptScore W2890745275C2776364478 @default.
• W2890745275 hasConceptScore W2890745275C2776396001 @default.
• W2890745275 hasConceptScore W2890745275C2778630268 @default.
• W2890745275 hasConceptScore W2890745275C502942594 @default.
• W2890745275 hasConceptScore W2890745275C54355233 @default.
• W2890745275 hasConceptScore W2890745275C553184892 @default.
• W2890745275 hasConceptScore W2890745275C62112901 @default.
• W2890745275 hasConceptScore W2890745275C81885089 @default.

• next